SFRP1 and glioma: Our results supplied additional evidence that miR‐542‐3p‐induced inhibition of SFRP1 and resultant SFRP1‐dependent blockade of the Wnt/β‐catenin pathway underpinned the tumor‐inhibitory effect of lncMEG3 elevation in glioma following MTE treatment.